Ina Research Co., Ltd.
Shin Nihon Kagaku Inari Research Center aims to be the best partner in pharmaceutical development by contributing to the realization of tomorrow's medical care through non-clinical trials. Established in 1974, the company specializes in safety evaluation and non-clinical testing for pharmaceuticals, chemicals, agricultural chemicals, and food products, with a focus on animal welfare and international standards.
Industries
Nr. of Employees
large (251-1000)
Ina Research Co., Ltd.
Services
End-to-end support for creation and validation of SEND datasets and packages for regulatory submission, including participation in SEND pilot programs.
Design and execution of toxicity studies from screening to preclinical repeat-dose studies to support clinical trial initiation.
Safety testing and data provision to support GHS classification, SDS creation and REACH registration.
Execution of the series of tests required for new agrochemical and formulation registration applications.
In vivo efficacy testing using established disease models to evaluate pharmacodynamic effects across CNS, ophthalmology and other therapeutic areas.
A range of analytical laboratory services including clinical testing, histopathology, metabolism assays and bioanalysis using on-site instrumentation.
End-to-end support for creation and validation of SEND datasets and packages for regulatory submission, including participation in SEND pilot programs.
Design and execution of toxicity studies from screening to preclinical repeat-dose studies to support clinical trial initiation.
Safety testing and data provision to support GHS classification, SDS creation and REACH registration.
Execution of the series of tests required for new agrochemical and formulation registration applications.
In vivo efficacy testing using established disease models to evaluate pharmacodynamic effects across CNS, ophthalmology and other therapeutic areas.
A range of analytical laboratory services including clinical testing, histopathology, metabolism assays and bioanalysis using on-site instrumentation.
Expertise Areas
- Nonclinical safety assessment and toxicology
- Pharmacology and in vivo efficacy testing
- GLP compliance and regulatory quality assurance
- SEND data management and regulatory submission support
Key Technologies
- SEND (Standard for Exchange of Nonclinical Data)
- Good Laboratory Practice (GLP)-compliant study conduct
- AAALAC-level animal welfare standards and accreditation
- CRISPR/Cas9 genome editing for disease models
News & Updates
Inari Research Center received full accreditation from AAALAC International on March 21, 2024.
Inari Research Center received compliance notifications for GLP inspections in November 2023 for pharmaceuticals, medical devices, and regenerative medicine products.
Inari Research Center changed its company name to Shin Nihon Kagaku Inari Research Center Inc. on October 1, 2024.
Research papers published by Shin Nihon Kagaku Inari Research Center, including recent collaborations and studies.
The company received full accreditation from AAALAC International, confirming animal welfare standards.
Inari Research Center received full accreditation from AAALAC International on March 21, 2024.
Inari Research Center received compliance notifications for GLP inspections in November 2023 for pharmaceuticals, medical devices, and regenerative medicine products.
Inari Research Center changed its company name to Shin Nihon Kagaku Inari Research Center Inc. on October 1, 2024.
Research papers published by Shin Nihon Kagaku Inari Research Center, including recent collaborations and studies.
The company received full accreditation from AAALAC International, confirming animal welfare standards.